CT characteristics of non-small cell lung cancer with epidermal growth factor receptor mutation: a systematic review and meta-analysis

BackgroundTo systematically investigate the relationship between CT morphological features and the presence of epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer (NSCLC).MethodsAll studies about the CT morphological features of NSCLC with EGFR mutations published between January 1, 2000 and March 15, 2015 were searched in the PubMed and EMBASE databases. Qualified studies were selected according to inclusion criteria. The frequency of EGFR mutations and CT features of ground-glass opacity (GGO) content, tumor size, cavitation, air-bronchogram, lobulation, and spiculation were extracted. The relationship between EGFR mutations and each of these CT features was tested based upon the weighted mean difference or inverse variance in the form of an odds ratio at a 95% confidence interval using Forest Plots. The publication bias was examined using Egger’s test.ResultsA total of 13 studies, consisting of 2146 NSCLC patients, were included, and 51.12% (1097/2146) of patients had EGFR mutations. The EGFR mutations were present in NSCLC with part-solid GGO in contrast to nonsolid GGO (OR = 0.49, 95% CI = 0.25–0.96, P = 0.04). Other CT features such as tumor size, cavitation, air-bronchogram, lobulation and spiculation did not demonstrate statistically significant correlation with EGFR mutations individually (P = 0.91; 0.67; 0.12; 0.45; and 0.36, respectively). No publication bias among the selected studies was noted in this meta-analysis (Egger’s tests, P > 0.05 for all).ConclusionThis meta-analysis demonstrated that NSCLC with CT morphological features of part-solid GGO tended to be EGFR mutated, which might provide an important clue for the correct selection of patients treated with molecular targeted therapies.

[1]  Chien-Jen Chen,et al.  Epidermal Growth Factor Receptor Mutation Status in Stage I Lung Adenocarcinoma with Different Image Patterns , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[2]  Jacques Ferlay,et al.  Estimates of cancer incidence in China for 2000 and projections for 2005. , 2005, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[3]  Ara A Vaporciyan,et al.  Tumor cavitation in stage I non-small cell lung cancer: epidermal growth factor receptor expression and prediction of poor outcome. , 2005, Radiology.

[4]  J. Goo,et al.  Imaging Characteristics of Stage I Non-Small Cell Lung Cancer on CT and FDG-PET: Relationship with Epidermal Growth Factor Receptor Protein Expression Status and Survival , 2013, Korean journal of radiology.

[5]  Alona Muzikansky,et al.  First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  A. Jemal,et al.  Global cancer statistics, 2012 , 2015, CA: a cancer journal for clinicians.

[7]  I. White,et al.  Quantifying the impact of between-study heterogeneity in multivariate meta-analyses , 2012, Statistics in medicine.

[8]  Pierre P Massion,et al.  Novel strategies for the early detection and prevention of lung cancer. , 2005, Seminars in oncology.

[9]  J. Doroshow Targeting EGFR in non-small-cell lung cancer. , 2005, The New England journal of medicine.

[10]  S. Fox,et al.  Molecular methods for somatic mutation testing in lung adenocarcinoma: EGFR and beyond. , 2015, Translational lung cancer research.

[11]  Michelle S. Ginsberg,et al.  Are There Imaging Characteristics Associated with Epidermal Growth Factor Receptor and KRAS Mutations in Patients with Adenocarcinoma of the Lung with Bronchioloalveolar Features? , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[12]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[13]  Kenji Suzuki,et al.  Molecular markers and changes of computed tomography appearance in lung adenocarcinoma with ground-glass opacity. , 2007, Japanese journal of clinical oncology.

[14]  A. Gemma,et al.  F1000 highlights , 2010 .

[15]  Y. Korogi,et al.  Adenocarcinomas with predominant ground-glass opacity: correlation of morphology and molecular biomarkers. , 2012, Radiology.

[16]  Hiroto Hatabu,et al.  State of the art: Response assessment in lung cancer in the era of genomic medicine. , 2014, Radiology.

[17]  T. Mok,et al.  Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. , 2009, The New England journal of medicine.

[18]  N. Müller,et al.  Fleischner Society: glossary of terms for thoracic imaging. , 2008, Radiology.

[19]  H Nakata,et al.  Evolution of peripheral lung adenocarcinomas: CT findings correlated with histology and tumor doubling time. , 2000, AJR. American journal of roentgenology.

[20]  Jae Ho Lee,et al.  Epidermal Growth Factor Receptor Mutation and Pathologic-Radiologic Correlation Between Multiple Lung Nodules with Ground-Glass Opacity Differentiates Multicentric Origin from Intrapulmonary Spread , 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[21]  G. Liu,et al.  Correlation Between EGFR Mutation Status and Computed Tomography Features in Patients With Advanced Pulmonary Adenocarcinoma , 2014, Journal of thoracic imaging.

[22]  Masaki Hara,et al.  Epidermal Growth Factor Receptor Gene Mutation and Computed Tomographic Findings in Peripheral Pulmonary Adenocarcinoma , 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[23]  M. Fishbein,et al.  Estrogen receptor signaling pathways in human non-small cell lung cancer , 2007, Steroids.

[24]  A. Jemal,et al.  Cancer statistics in China, 2015 , 2016, CA: a cancer journal for clinicians.

[25]  J. Engelman,et al.  Ceritinib in ALK-rearranged non-small-cell lung cancer. , 2014, The New England journal of medicine.

[26]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[27]  I. Takeyoshi,et al.  Correlation between computed tomography findings and epidermal growth factor receptor and KRAS gene mutations in patients with pulmonary adenocarcinoma. , 2011, Oncology reports.

[28]  D. Moher,et al.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. , 2010, International journal of surgery.

[29]  Jeffrey W. Clark,et al.  Crizotinib in ROS 1-Rearranged Non – Small-Cell Lung Cancer , 2014 .

[30]  Gillian Ellison,et al.  EGFR mutation testing in lung cancer: a review of available methods and their use for analysis of tumour tissue and cytology samples , 2012, Journal of Clinical Pathology.

[31]  Alexander J Sutton,et al.  What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. , 2004, Statistics in medicine.

[32]  J. Goo,et al.  EGFR gene copy number in adenocarcinoma of the lung by FISH analysis: investigation of significantly related factors on CT, FDG-PET, and histopathology. , 2009, Lung cancer.

[33]  F. Cappuzzo,et al.  First-line crizotinib versus chemotherapy in ALK-positive lung cancer. , 2014, The New England journal of medicine.

[34]  Masahiro Tsuboi,et al.  International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[35]  M. Matoba,et al.  Relationships between EGFR mutation status of lung cancer and preoperative factors - are they predictive? , 2014, Asian Pacific journal of cancer prevention : APJCP.

[36]  Ming Liu,et al.  EGFR L858R mutation is associated with lung adenocarcinoma patients with dominant ground-glass opacity. , 2015, Lung cancer.

[37]  Lu Wang,et al.  Response to Cabozantinib in patients with RET fusion-positive lung adenocarcinomas. , 2013, Cancer discovery.

[38]  Sunil Singhal,et al.  Prognostic Implications of Cell Cycle, Apoptosis, and Angiogenesis Biomarkers in Non–Small Cell Lung Cancer: A Review , 2005, Clinical Cancer Research.

[39]  J. Minna,et al.  Exclusive mutation in epidermal growth factor receptor gene, HER‐2, and KRAS, and synchronous methylation of nonsmall cell lung cancer , 2006, Cancer.

[40]  William Pao,et al.  Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond , 2008, Modern Pathology.

[41]  N. Normanno,et al.  Epidermal growth factor-related peptides and their receptors in human malignancies. , 1995, Critical reviews in oncology/hematology.

[42]  A. Jemal,et al.  Cancer statistics, 2015 , 2015, CA: a cancer journal for clinicians.

[43]  E. Felip,et al.  Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. , 2012, The Lancet. Oncology.

[44]  J. Engelman,et al.  Ceritinib in ALK-rearranged non-small-cell lung cancer. , 2014, The New England journal of medicine.

[45]  S. Goodman,et al.  An Epigenetic Marker Panel for Detection of Lung Cancer Using Cell-Free Serum DNA , 2011, Clinical Cancer Research.

[46]  N. Dubrawsky Cancer statistics , 1989, CA: a cancer journal for clinicians.

[47]  S. Gabriel,et al.  EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.

[48]  Kyung Soo Lee,et al.  Ground-glass Opacity Nodules: Histopathology, Imaging Evaluation, and Clinical Implications , 2011, Journal of thoracic imaging.

[49]  Lawrence H. Schwartz,et al.  Epidermal growth factor receptor mutation in lung adenocarcinomas: relationship with CT characteristics and histologic subtypes. , 2013, Radiology.

[50]  A. Gazdar Personalized medicine and inhibition of EGFR signaling in lung cancer. , 2009, The New England journal of medicine.